Shots

• Gilead signs a non-exclusive licensing agreement with Zydus to manufacture and distribute remdesivir- under which Zydus to receive the manufacturing know-how from Gilead to manufacture the API for remdesivir and the finished product and market it in 127 countries- including India
• The license is royalty-free until another pharmaceutical product or vaccine receives the US FDA and EMA’s approval for COVID 19 or the WHO announcing the end of the public health emergency. Zydus will ramp up the production to reach patients across the 127 countries including India in Gilead’s global patient solution region
• Additionally- Gilead signed a non- exclusive agreement with Dr. Reddy’s to register- manufacture and commercialize Gilead’s remdesivir for Covid-19 in 127 countries including India. Dr. Reddy’s will receive Gilead’s technology transfer for manufacturing scale-up and obtain regulatory approval for marketing of therapy in respective countries

Click here- Click here to read full press release/ article 

Ref: Zydus- Businesswire | Image: Gilead

Related News: Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries